Abstract To evaluation of the clinical efficacy of high intensity focused ultrasound (HIFU) of patients with uterine fibroids. Methods: 56 patients with uterine fibroids were treated by HIFU from July 2016 to July 2019. Before and after treatment, the symptom scores and the scores of health-related quality of life (UFS-QOL) of these patients were evaluated by questionnaires, their volumes of uterine fibroid were measured, their levels of immune-related indicators were detected, and the change of estrogen receptor (ER) and Bcl-2 levels of the patients were analyzed. Results: The volume of uterine fibroids of the patients 1, 3, 6 and 12 months after treatment were 21.72± 3.65cm3, 13.42± 2.38cm3, 8.72±1.87cm3, and 5.72±1.02 cm3, respectively, which had decreased gradually (P<0.05). The symptom scores of the patients 1, 3, 6 and 12 months after treatment were 16.26±3.95 points, 14.13±2.05 points, 8.84±1.21 points, and 5.03±0.62 points, respectively, which had decreased gradually (P<0.05). The score of UFS-QOL of the patients at 1, 3, 6 and 12 months after treatment were 82.65±7.02 points, 87.04±7.86 points, 93.87±8.75 points, 98.02±9.54 points, respectively, which had increased gradually (P<0.05). 1 month after treatment, the immune-related indicators, such as the levels of CD3+, CD4+, CD8+, CD4+/CD8+, and NK of patients were all significant higher than those before treatment, but the levels of estrogen receptor ER and bcl-2 expression were significant lower than before treatment (P<0.05). Conclusion: High intensity focused ultrasound for treating patients with uterine fibroids can reduce the volume of the tumor significantly, can alleviate the clinical symptoms, and can improve the quality of life of patients.
|
